Strata skin sciences, inc. announces inducement grants under nasdaq listing rule 5635(c)(4)

Horsham, pa., oct. 31, 2023 (globe newswire) -- strata skin sciences, inc. (nasdaq: sskn) (the “company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that, as previously reported on its form 8-k filed on october 30, 2023, effective as of the close of trading on october 31, 2023, the company granted equity-based awards, in accordance with nasdaq listing rule 5635(c)(4), to dr. dolev rafaeli as an inducement material to dr. rafaeli entering into an employment agreement with the company and commencing employment as its vice-chairman, chief executive officer and president. dr. rafaeli received an equity-based award of a stock option to purchase 1,754,569 shares of the company's common stock, with a strike price of $0.53 per share, vesting over a three-year period, with 145,465 options vesting on january 31, 2024, and 145,464 options vesting every three months thereafter, provided in general that dr. rafaeli remains in the company's employ through each applicable vesting date and subject to the terms and conditions of the applicable award agreement.
SSKN Ratings Summary
SSKN Quant Ranking